1. Ablynx [Internet]. [2009]. Ghent, Belgium. [cited 2010 Mar 26]. Available from: http://www.ablynx.com
2. Carter P, Merchant AM. 1997. Engineering antibodies for imaging and therapy. Current Opinion in Biotechnology. 8:449-454.
3. Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, et al. 2006. Formatted anti-tumor necrosis factor VHH proteins derived from camelids show superior potency and targeting to inflamed joint sin a murine model of collagen-induced arthritis. Arthritis and Rheumatism. 54(6): 1856-1866
4. Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI. 2000. Mapping the glycoprotein Ib-binding site in the von Willebrand Factor A1 domain. The Journal of Biological Chemistry. 275(25):19098-19105.
5. De Genst E, Silence K, Decanniere K , Conrath K, Loris R, Kinne J, Muyldermanns S, Wyns L. 2006. Molecular basis for the preferential cleft recognition by dromedary heavy chain antibodies. PNAS. 103(12):4586-4591.
6. De Meyre SF, De Maeyer B, Deckmyn H, Vanhoorelbeke K. 2009. Von Willebrand factor: drug and drug target. Cardiovascular & Haematological Disorders-Drug Targets. 9:9-20.
7. Elgert KD. 2009. Immunology: Understanding the Immune System. 2nd Edition. Hoboken, New Jersey: Wiley-Blackwell.
8. Deffar K, Shi H, Li L, Wang X, Zhu X. 2009. Nanobodies - the new concept in antibody engineering. African Journal of Biotechnology. 8(12):2645-2652.
9. Harmsen MM, De Haard HJ. 2007. Properties, production and applications of camelid single-domain antibody fragments. Applied Microbiology Biotechnology. 77:13-22.
10. Huizinga EG, Tsuji S, Romijn RAP, Schiphost ME, de Groot PG, Sixma JJ, Gros P. 2002. Structures of GPIb and its complex with vWF A1 domain. Science. 297:1176-1179.
11. Journal of Thrombosis and Haemostasis; Volume 5, Supplement 2: AS-TH-024
12. Journal of Thrombosis an dHaemostasis; Volume 5, Supplement 2: PP-WE-416
13. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. 2009. Target therapy of cancer: Implmenetation of monoclonal antibodies and nanobodies. Human Antibodies. 18:81-1
14. Muyldermans S. 2001. Single domain camel antibodies: current status. Molecular Biotechnology. 74:277-302.
16. Revets H, De Baetselier P, Muyldermans S. 2005. Nanobodies as novel agents for cancer therapy. Expert Opinion on Biological Therapy. 5(1):111-124.
17. Rabinowitz I, Tuley EA, Mancuso DJ, RANDI AM, Firkin BG, Howard MA, Sadler JE. 1992. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Medical Sciences. 89:9846-9849.
18. Siller-Matula JM, Krumphuber J, Jilma B. 2010. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. British Journal of Pharmacology. 159:502-517.
19. Van Bockstaele F, Holz J, Revets H. 2009. The development of nanobodies for therapeutic application. Current Opinion in Investigational Drugs. 10(11):1212-1224.
20. Weslolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Schwartz N, et al. 2009. Single Domain Antibodies: promising experimental and therapeutic tools in infection and immunity. Medical Microbiology and Immunology. 198:157-174.
References
1. Ablynx [Internet]. [2009]. Ghent, Belgium. [cited 2010 Mar 26]. Available from: http://www.ablynx.com
2. Carter P, Merchant AM. 1997. Engineering antibodies for imaging and therapy. Current Opinion in Biotechnology. 8:449-454.
3. Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, et al. 2006. Formatted anti-tumor necrosis factor VHH proteins derived from camelids show superior potency and targeting to inflamed joint sin a murine model of collagen-induced arthritis. Arthritis and Rheumatism. 54(6): 1856-1866
4. Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI. 2000. Mapping the glycoprotein Ib-binding site in the von Willebrand Factor A1 domain. The Journal of Biological Chemistry. 275(25):19098-19105.
5. De Genst E, Silence K, Decanniere K , Conrath K, Loris R, Kinne J, Muyldermanns S, Wyns L. 2006. Molecular basis for the preferential cleft recognition by dromedary heavy chain antibodies. PNAS. 103(12):4586-4591.
6. De Meyre SF, De Maeyer B, Deckmyn H, Vanhoorelbeke K. 2009. Von Willebrand factor: drug and drug target. Cardiovascular & Haematological Disorders-Drug Targets. 9:9-20.
7. Elgert KD. 2009. Immunology: Understanding the Immune System. 2nd Edition. Hoboken, New Jersey: Wiley-Blackwell.
8. Deffar K, Shi H, Li L, Wang X, Zhu X. 2009. Nanobodies - the new concept in antibody engineering. African Journal of Biotechnology. 8(12):2645-2652.
9. Harmsen MM, De Haard HJ. 2007. Properties, production and applications of camelid single-domain antibody fragments. Applied Microbiology Biotechnology. 77:13-22.
10. Huizinga EG, Tsuji S, Romijn RAP, Schiphost ME, de Groot PG, Sixma JJ, Gros P. 2002. Structures of GPIb and its complex with vWF A1 domain. Science. 297:1176-1179.
11. Journal of Thrombosis and Haemostasis; Volume 5, Supplement 2: AS-TH-024
12. Journal of Thrombosis an dHaemostasis; Volume 5, Supplement 2: PP-WE-416
13. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. 2009. Target therapy of cancer: Implmenetation of monoclonal antibodies and nanobodies. Human Antibodies. 18:81-1
14. Muyldermans S. 2001. Single domain camel antibodies: current status. Molecular Biotechnology. 74:277-302.
15. Nested Primers for PCR [Internet]. [2002]. Department of Biology, Davidson College, Davidson, North Carolina, USA. [cited 2010 Apr 06]. Available from: http://www.bio.davidson.edu/courses/genomics/method/NestedPCR.html
16. Revets H, De Baetselier P, Muyldermans S. 2005. Nanobodies as novel agents for cancer therapy. Expert Opinion on Biological Therapy. 5(1):111-124.
17. Rabinowitz I, Tuley EA, Mancuso DJ, RANDI AM, Firkin BG, Howard MA, Sadler JE. 1992. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Medical Sciences. 89:9846-9849.
18. Siller-Matula JM, Krumphuber J, Jilma B. 2010. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. British Journal of Pharmacology. 159:502-517.
19. Van Bockstaele F, Holz J, Revets H. 2009. The development of nanobodies for therapeutic application. Current Opinion in Investigational Drugs. 10(11):1212-1224.
20. Weslolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Schwartz N, et al. 2009. Single Domain Antibodies: promising experimental and therapeutic tools in infection and immunity. Medical Microbiology and Immunology. 198:157-174.